No profile data available.
Eagle Pharmaceuticals, Inc. (EGRX) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Woodcliff Lake, United States, with about 134 full-time employees.
It reported revenue of $316.61 million for fiscal year 2022, up 84.6% from fiscal year 2021, and net income of $35.64 million. In Q2 2023 (the quarter ended June 30, 2023) revenue was $64.65 million, down 12.8% from a year before. Its market capitalization was $3.29 million as of February 5, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2022; market data as of February 5, 2026.
, a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States.
Eagle Pharmaceuticals reported $316.61 million in revenue for fiscal year 2022, up 84.6% from $171.55 million in fiscal year 2021. In Q2 2023 revenue was $64.65 million.
$3.29 million as of February 5, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Acusphere, Inc. (ACUS), For The Earth Corp. (FTEG), Bhang Inc. (BHNGF), Revelation Biosciences, Inc. (REVB).